Larry D Cripe MD
Associate Professor, Medicine, Indiana University School of Medicine
Join to view full profile
535 Barnhill Dr# ROUTE473Indianapolis, IN 46202
Phone+1 317-278-1186
Fax+1 317-944-2181
Dr. Cripe is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 1987 - 1990
Rush University Medical CenterResidency, Internal Medicine, 1984 - 1987
Rush Medical College of Rush University Medical CenterClass of 1984
Certifications & Licensure
IN State Medical License 1995 - 2027
NC State Medical License 1987 - 1998
MI State Medical License 1993 - 1997
IL State Medical License 1985 - 1987
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification P2 Sentinel, Cerner Corporation, 2015, 2017
- CMS Meaningful Use Stage 1 Certification Cerner Patient Portal and Powerchart, Cerner Corporation, 2015, 2017
- CMS Meaningful Use Stage 1 Certification PowerChart (CQM), Cerner Corporation, 2015, 2017
Clinical Trials
- Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Start of enrollment: 2002 Sep 17
- Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes
- Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease
Publications & Presentations
PubMed
- Elevated levels of TNF and its targets characterize better-risk older acute myeloid leukemia patients.Yaseswini Neelamraju, Franck Rapaport, Jorge A Gandara, B Bishal Paudel, Susan DeWolf
Leukemia. 2026-05-01 - 4 citationsNCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026.William G Wierda, Jennifer Brown, Jeremy S Abramson, Farrukh Awan, Greg Bociek
Journal of the National Comprehensive Cancer Network. 2026-03-01 - FLT3-SYK inhibitor and Ixazomib combination impact HOXA and oxidative stress control by β-catenin, SQSTM1 and NRF2 in AML.Santhosh Kumar Pasupuleti, Sravanti Rangaraju, Justin Layer, Kanaka Sai Ram Padam, Larry D Cripe
NPJ Precision Oncology. 2026-02-26
Press Mentions
NCCN Awards Grants to Improve Care for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaDecember 4th, 2024- Chuckstrong Tailgate Gala Raises More Than $2 Million, Marking a Decade of Dedication to IU Cancer ResearchAugust 5th, 2022
- Cancer Interrupted Campus ‘Dad’s Weekend’ for Devoted FatherOctober 3rd, 2021
Grant Support
- Single-Center Phase I Study To Determine The Optimal Biologic Dose Of Cc-401National Center For Research Resources2007–2008
- Zosuquidar Trihydrochloride During Conventional Induction And Post-RemissionNational Center For Research Resources2006
- Clinical Research OfficeNational Cancer Institute2004
- Ly335979, Daunorubicin, Cytarabine In Myelogenous LeukemNational Center For Research Resources2000–2002
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
